赛诺菲斥资高达 22 亿美元收购 Inhibrx，寻找尖端药物，并减少对 Dupixent 的依赖。 Sanofi purchases Inhibrx for up to $2.2 billion, looks for cutting-edge medications, and lessens reliance on Dupixent.

法国制药商赛诺菲同意以高达 22 亿美元的价格收购美国生物技术公司 Inhibrx Inc.。 Sanofi, a French drugmaker, agreed to buy the U.S. biotech firm Inhibrx Inc. for up to $2.2 billion. 此次收购旨在支持赛诺菲推动创新药物的发展，并减少对其重磅哮喘药物 Dupixent 的依赖。 The acquisition aims to support Sanofi's push for innovative medicines and reduce dependence on its blockbuster asthma medicine, Dupixent. Inhibrx 的创始人兼首席执行官 Mark Lappe 将在赛诺菲的支持下与其他研究人员和员工一起经营一家分拆公司。 Inhibrx's founder and CEO, Mark Lappe, will run a spinoff with the rest of the research and employees, supported by Sanofi.